Skip to main content

Health condition · Clinically reviewed

Chronic lymphocytic leukaemia, from watchful waiting to targeted therapy.

A slow-growing blood cancer of mature B lymphocytes. Many people are monitored for years; when treatment is needed, modern targeted therapies have transformed outcomes.

Jump to treatment
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Clinically reviewed

    Written by our editorial team and reviewed by a registered UK clinician before publication.

  • 02

    Sourced from guidance

    Checked against BSH, NICE, ESMO and peer-reviewed haematology sources you can see at the end.

  • 03

    Current for 2026

    Reflects modern UK practice including BTK inhibitors, venetoclax-obinutuzumab and CAR-T for relapsed disease.

Key facts

CLL at a glance.

The essentials, in plain English. What CLL is, how it is found, and how modern UK practice treats it in 2026.

  • What it is

    A clonal proliferation of mature B lymphocytes. CLL circulates in blood and marrow; SLL is the same disease with a nodal distribution.

  • Who it affects

    The most common leukaemia in Western adults, with a median age in the 70s and a modest male predominance.

  • How it is found

    Often incidentally on a routine FBC showing lymphocytosis, before any symptoms appear.

  • What guides therapy

    IGHV mutation status and FISH for del(17p) or TP53 mutation shape whether and how to treat.

  • Modern first line

    Continuous BTK inhibitors or fixed-duration venetoclax with obinutuzumab have largely replaced older chemoimmunotherapy.

  • Living with it

    Many people never need treatment. Others live well for years on targeted oral therapies with regular haematology review.

Why this guide matters

A different disease from the one it used to be.

The last decade has reshaped CLL care. Three ideas sit behind everything else on this page.

  • Not every CLL needs treatment

    Most Binet A and Rai 0 disease is monitored, not treated. Early therapy does not improve survival, and watchful waiting is active care with a purpose.

  • Genomics guides the plan

    IGHV mutation status and TP53 or del(17p) findings decide whether chemoimmunotherapy is safe or targeted therapy is essential.

  • Targeted therapy has changed outcomes

    BTK inhibitors and venetoclax-based regimens have largely replaced older chemotherapy, with fewer late toxicities and better long-term control.

How the diagnosis is made

From a raised lymphocyte count to a clear plan.

The steps a UK haematology team will normally follow, in order. Diagnosis is largely a blood test story; bone marrow biopsy is rarely required.

  1. 01

    Confirming

    FBC and blood film

    Persistent mature lymphocytosis with characteristic smudge cells on the film raises the suspicion of CLL.

  2. 02

    Confirming

    Flow cytometry

    Immunophenotyping is the diagnostic test. A Matutes score using CD5, CD19, CD20, CD23, CD79b or FMC7 and surface immunoglobulin confirms CLL.

  3. 03

    Confirming

    Clinical staging

    Examination for lymphadenopathy, splenomegaly and hepatomegaly is used to assign a Rai (0 to IV) or Binet (A, B or C) stage.

  4. 04

    Characterising

    Molecular and cytogenetics

    FISH for del(17p), del(11q), trisomy 12 and del(13q), plus IGHV mutation status and a TP53 sequencing panel, guide treatment choice.

  5. 05

    Characterising

    Imaging when needed

    CT of neck, chest, abdomen and pelvis is used before starting therapy or when transformation is suspected. Marrow biopsy is rarely required for diagnosis.

  6. 06

    Characterising

    Baseline safety bloods

    Immunoglobulins, direct Coombs test, LDH, urate, renal and liver function, and screening for hepatitis B, HIV and CMV before therapy.

  7. 07

    Planning

    Shared plan with haematology

    A specialist MDT sets a plan: active monitoring for early-stage disease, or targeted therapy with clear indications and monitoring.

Typical timeline: a first abnormal count to a confirmed diagnosis and plan in weeks, not months.

Symptoms

What CLL actually looks like.

Many people have no symptoms at all. When they appear, they are often gradual, with a distinctive mix of features that steer the diagnosis.

  • Incidental lymphocytosis

    Raised lymphocyte count on a routine FBC is the most common way CLL is first noticed.

  • Painless lymphadenopathy

    Rubbery, mobile, non-tender lymph nodes, often in the neck, axillae or groin.

  • Splenomegaly and hepatomegaly

    A palpable spleen or liver can cause early satiety or left-sided fullness.

  • B symptoms

    Fatigue, unintentional weight loss, drenching night sweats or fevers without infection.

  • Recurrent infections

    Impaired antibody responses and hypogammaglobulinaemia make chest and sinus infections more common.

  • Autoimmune cytopenias

    Autoimmune haemolytic anaemia, immune thrombocytopenia or pure red cell aplasia can develop and need targeted treatment.

  • Second cancers

    Higher risk of skin and other solid cancers means regular skin checks and prompt review of new symptoms matter.

  • Red flag - Richter transformation

    Rapidly enlarging nodes, high LDH or new B symptoms can signal transformation to an aggressive lymphoma and need urgent review.

Treatment

How CLL is treated in the UK.

Active monitoring is the default for asymptomatic early-stage disease. When treatment is indicated, BTK inhibitors and venetoclax-based regimens sit at the front line, with CAR-T and transplant reserved for selected relapsed disease.

  • Active monitoring

    For asymptomatic early-stage disease (most Binet A and Rai 0), watchful waiting with regular reviews. Early treatment does not improve survival.

  • BTK inhibitors

    Ibrutinib, acalabrutinib, zanubrutinib and pirtobrutinib are continuous daily oral therapies, taken until progression or intolerance.

  • Venetoclax with obinutuzumab

    A 12-month fixed-duration regimen based on the CLL14 trial. A practice-changing option for time-limited therapy.

  • Venetoclax-based combinations

    Venetoclax with ibrutinib and other combinations offer fixed-duration, all-oral targeted regimens in selected patients.

  • High-risk pathway

    For del(17p) or TP53 mutation, targeted therapy (BTK inhibitor or venetoclax) is essential. Allogeneic stem cell transplant is considered for selected younger patients.

  • Chemoimmunotherapy

    FCR (fludarabine, cyclophosphamide, rituximab) and BR (bendamustine, rituximab) still have a limited role, largely for younger fit patients with IGHV-mutated disease and no del(17p).

  • Relapsed and refractory

    Options include switching between BTK and BCL-2 inhibitors, PI3K inhibitors in selected cases, CAR-T (lisocabtagene, approved for CLL and SLL in 2024), bispecific antibodies and allogeneic transplant.

  • Supportive care

    Infection prophylaxis, immunoglobulin replacement for recurrent infections with hypogammaglobulinaemia, and inactivated vaccines including COVID, influenza, pneumococcal and shingles (Shingrix). Live vaccines are avoided.

When treatment starts

Treatment is triggered by disease, not by numbers alone.

Standard iwCLL indications include progressive marrow failure (falling haemoglobin or platelets), B symptoms, massive or symptomatic lymphadenopathy or splenomegaly, autoimmune cytopenias that do not respond to steroids, and a lymphocyte doubling time under six months.

What this guide is based on

The sources behind every claim on this page.

UK and international haematology guidance, current at the time of last review.

Key references

Guidelines and standards we relied on.

A quiet reminder

This guide is for information, not medical advice.

Your haematology team knows your bloods, imaging and history in a way this page cannot. If in doubt, ask them what applies to you.

  • British Society for Haematology (BSH). Guidelines on the diagnosis, investigation and management of CLL.

  • NICE. Technology appraisals covering ibrutinib, acalabrutinib, zanubrutinib and venetoclax combinations for CLL.

  • ESMO. Clinical Practice Guidelines for chronic lymphocytic leukaemia.

  • iwCLL. International Workshop on CLL response criteria and treatment indications.

Red flags

When CLL needs urgent attention.

Most CLL is stable and manageable. These are the situations that are not, and where the haematology team wants to hear from you quickly.

  • Richter transformation

    Rapidly enlarging nodes, marked rise in LDH or new B symptoms may indicate transformation to diffuse large B-cell lymphoma or Hodgkin lymphoma. Urgent haematology review is needed.

  • Severe or recurrent infection

    Fever, breathlessness or new confusion in someone with CLL needs prompt medical assessment. Neutropenic sepsis is a medical emergency.

  • Autoimmune cytopenias

    Sudden anaemia, jaundice or bruising can reflect autoimmune haemolytic anaemia or immune thrombocytopenia and need urgent review.

  • Progressive marrow failure

    Falling haemoglobin, platelets or neutrophils driven by marrow infiltration is a clear treatment indication.

  • Rapid lymphocyte doubling

    A doubling time under six months, or a rise of more than 50 per cent over two months, is one of the classical triggers to start therapy.

  • New neurological symptoms

    Headache, confusion or focal weakness may signal CNS involvement or infection and need urgent imaging and review.

  • Suspicious skin lesions

    People with CLL have a higher risk of skin cancers, including aggressive squamous cell carcinoma and melanoma. Any changing lesion deserves prompt review.

  • Tumour lysis on treatment

    Venetoclax carries a real risk of tumour lysis syndrome. Ramp-up dosing, hydration and monitoring are essential.

  • Bleeding on BTK inhibitors

    BTK inhibitors can increase bleeding. Report new bruising, nosebleeds or planned surgery so treatment can be paused safely.

Living with it

A long, largely liveable diagnosis, with the right team.

Four things that make the biggest difference day to day. Regular monitoring, sensible infection prevention, skin protection and knowing where to turn for support.

A quiet reminder

Watchful waiting is not doing nothing.

It is a deliberate strategy that avoids unnecessary treatment while catching change early. Keep your appointments, even when you feel completely well.

  1. 01 Monitoring

    Watchful waiting is active care

    Regular reviews with FBC and examination catch changes early. Treatment starts when there is a clear indication, not just a rising count.

  2. 02 Infection

    Vaccinate and prevent

    Keep COVID, influenza, pneumococcal and shingles (Shingrix) vaccines up to date. Avoid live vaccines. Ask about prophylactic aciclovir or co-trimoxazole if you are on targeted therapy.

  3. 03 Skin

    Sun protection and skin checks

    Daily SPF, hats and annual dermatology review reduce the risk of skin cancers, which are more common in CLL.

  4. 04 Support

    You are not alone

    Blood Cancer UK, CLLSA and Lymphoma Action offer information, peer support and helplines throughout the journey.

Frequently asked

Everything we get asked about CLL.

Quick answers on watchful waiting, IGHV and TP53, BTK inhibitors, venetoclax, Richter transformation and vaccines.

  • What is chronic lymphocytic leukaemia?

    CLL is a slow-growing blood cancer where mature B lymphocytes accumulate in the blood, bone marrow, lymph nodes and spleen. Small lymphocytic lymphoma (SLL) is the same disease with a mainly nodal distribution rather than a high blood count.

  • Do I need treatment straight away?

    Usually not. Most people with early-stage CLL (Binet A or Rai 0) are monitored rather than treated. Starting therapy earlier does not improve survival. Treatment begins when there are clear indications such as progressive marrow failure, B symptoms, rapidly rising counts, bulky or symptomatic disease or refractory autoimmune cytopenias.

  • Why are IGHV status and TP53 important?

    IGHV mutation status and FISH or sequencing for TP53 and del(17p) predict how the disease behaves and how it responds to different treatments. Unmutated IGHV and TP53 abnormalities mean chemoimmunotherapy should be avoided and targeted therapies are essential.

  • What are BTK inhibitors and venetoclax?

    BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib and, in resistant disease, pirtobrutinib) are daily oral drugs taken continuously. Venetoclax is a BCL-2 inhibitor, most often given for a fixed 12 months with the anti-CD20 antibody obinutuzumab. Together they have largely replaced older chemotherapy for first-line treatment.

  • What is Richter transformation?

    In around five per cent of cases, CLL transforms into an aggressive lymphoma, most commonly diffuse large B-cell lymphoma and occasionally Hodgkin lymphoma. Rapidly enlarging nodes, a marked rise in LDH or new B symptoms should prompt urgent haematology review, including biopsy and imaging.

  • Which vaccines are safe with CLL?

    Inactivated vaccines are safe and recommended, including annual influenza, COVID boosters, pneumococcal vaccines and the recombinant shingles vaccine (Shingrix). Live vaccines such as yellow fever, live shingles (Zostavax) and MMR should generally be avoided. Response to vaccines is often reduced, so household vaccination and infection precautions matter too.

Related content

Keep reading.

Pulse Healthcare concierge

Send us your enquiry

A concierge service for UK private healthcare. We match you with the best vetted clinics and consultants in our network - they then contact you directly.

So we can match you to the right clinician close to you.

We reply to every enquiry within 24 hours (Mon–Fri). Confidential - your details are never shared outside our vetted consultant network.